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Body mass index (BMI) is an independent risk factor for luminal-type breast cancer in Western populations.
However, it is unclear whether the impact of BMI differs according to breast cancer subtype in Japanese
populations. We conducted a case–control study with 715 cases and 1430 age- and menopausal status-matched
controls to evaluate the associations of BMI and its change (from age 20 years to the current age) with breast
cancer risk. We applied conditional logistic regression models to estimate odds ratios (ORs) and 95% confidence
intervals (CIs). Tumor subtypes were divided into four subtypes, namely the luminal, luminal/HER2, HER2-rich, and
triple-negative subtypes. Current BMI and BMI change were positively associated with postmenopausal breast
cancer risk. On stratified analysis by tumor subtype, we observed associations between current BMI and BMI change
and postmenopausal breast cancer risk for the luminal subtype, with OR for each 1 kg/m2 increase in current BMI of
1.14 (95% CI: 1.07 - 1.20) and the corresponding OR of BMI change of 1.16 (1.09 - 1.23) (each Ptrend < 0.001).
Additionally, we found the same tendency for the triple-negative subtype, with the OR for a 1 kg/m2 increase in
current BMI of 1.21 (1.05 - 1.39) and that for BMI change of 1.18 (1.02 - 1.36) (Ptrend was 0.008 and 0.024,
respectively). In premenopausal women, a suggestive inverse association was observed between BMI change and
breast cancer risk for the luminal subtype only, with OR of BMI change of 0.93 (0.87 - 1.00, Ptrend = 0.054). No
association was seen between BMI at age 20 years and risk of any tumor subtype. In conclusion, BMI and its change
are associated with the risk of both luminal and triple-negative breast cancer among postmenopausal Japanese
women. These findings suggest the etiological heterogeneity of breast cancer among tumor subtypes.
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The rapid increase in the incidence rate of breast cancer
over the last quarter of a century in Japan (Matsuda et al.
2011) can be related to changes in the prevalence of estab-
lished risk factors, such as reproductive and anthropomet-
ric factors (Minami et al. 2004). Among these, obesity is
an important and potentially modifiable risk factor for* Correspondence: kmatsuo@aichi-cc.jp
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in any medium, provided the original work is pbreast cancer, the incidence of which is increasing in most
countries (World Health Organization 2011). In Japan
also, body mass index (BMI) has consistently increased in
older women, albeit that the prevalence of obesity remains
lower than in Western countries (Funatogawa et al. 2009;
OECD 2010).
The association between high BMI or adult weight
gain and breast cancer risk for postmenopausal women
has been established, and found to be partly attributable
to an increase in circulating endogenous estrogen levels
from adipose tissue, the primary source of estrogen in
postmenopausal women (Han et al. 2006; Kawai et al.
2010; Eliassen et al. 2006). These findings are supportedOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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postmenopausal breast cancer is stronger for estrogen
receptor (ER)-positive than -negative tumors (Feigelson
et al. 2006; Vrieling et al. 2010; Suzuki et al. 2011).
The clinical relevance of molecular subtypes of breast
cancer has been demonstrated. These appear to include at
least four major tumor subtypes defined by ER, progester-
one receptor (PR), and human epidermal growth factor re-
ceptor 2 (HER2) status, (Perou et al. 2000; Sorlie et al.
2001). Although these distinct subtypes have been asso-
ciated with different clinical outcomes (Sotiriou et al. 2003),
evidence on etiologic differences among them is limited.
Some epidemiological studies have shown that reproductive
factors and BMI are associated with an increased risk of
only ER- and/or PR-positive tumors (Phipps et al. 2011;
Phipps et al. 2008), but others have suggested that ER- and
PR-negative tumors are also positively associated with BMI
(Yang et al. 2011; Yang et al. 2007). These studies were con-
ducted mainly in Western populations, however, and the
findings have not been entirely consistent. Additionally, po-
tential biological differences among cancers may be present,
and the prevalence of obesity differs between Western and
Asian countries. These issues thus highlight the importance
of evaluating the impact of BMI and its change on breast
cancer risk by tumor subtype in Asian populations.
Here, we conducted a case–control study to evaluate
associations between BMI and breast cancer risk by




Case subjects were 715 female cancer patients with no
previous history of breast cancer who initially visited
Aichi Cancer Center Hospital (ACCH) in Nagoya, Japan,
between January 2001 and June 2005. Control subjects
were 1430 age- and menopause-matched females with-
out any history of cancer, giving a 1:2 case–control ratio.
All subjects were selected from the database of the
Hospital-based Epidemiologic Research Program at
Aichi Cancer Center (HERPACC), the framework of
which has been described elsewhere (Tajima et al. 2000;
Hamajima et al. 2001). In brief, 23408 HERPACC-
enrolled first-visit outpatients were asked to provide in-
formation on lifestyle factors and blood samples for
genetic studies. Approximately 95% of eligible subjects
completed a self-administered questionnaire, responses
to which were checked by a trained interviewer, and 55%
provided blood samples. We selected women as cases
whose histological diagnosis was available and whose
ER, PR and HER2 status results were confirmed. We
used cancer-free patients at our hospital as controls
given the likelihood that our case subjects arose within
this population base. We previously showed that thegeneral lifestyle of cancer-free outpatients at our hospital
was in accord with that of a general population ran-
domly selected from the electoral roll of Nagoya City,
Aichi Prefecture, confirming the feasibility of their use
as controls in epidemiological studies (Inoue et al. 1997).
The present study was approved by the Institutional Eth-
ics Review Board of ACC, and all participants gave writ-
ten informed consent.
Evaluation of environmental factors
The HERPACC questionnaire included items on height
and weight, weight at age 20 years, menopausal status,
parity and lactation, drinking and smoking habits, exer-
cise, hormone use, individual medical history, family his-
tory of cancer, and referral pattern to our hospital.
Patients were asked to provide information on their life-
style at one year before the onset of symptoms for those
who were symptomatic, or at the time of interview for
those who were asymptomatic.
BMI at current age and at age 20 years was calculated
as the weight divided by the squared height (kg/m2) and
divided into four groups, < 18.5, ≥ 18.5 to < 22, ≥ 22 to
< 25, and ≥ 25. BMI at current age was referred to BMI
at cancer diagnosis. Although the cut-off points of BMI
for underweight/normal/overweight/obese under the
World Health Organization (WHO) definition are
< 18.5, ≥ 18.5 to < 25, ≥ 25 to < 30, and ≥ 30, respect-
ively (World Health Organization 2012), we combined
the overweight and obese groups and divided the normal
group into two subgroups in consideration of the low
prevalence of obesity in Japan. BMI change from age 20
years to the current age was calculated as the difference
between current BMI and BMI at age 20, and was also
categorized into six groups, with a BMI loss of < −4, or
≥ −4 to < −2; stable BMI of ≥ −2 to < +2; and BMI gain
of ≥ +2 to < +5, ≥ +5 to < +8, and ≥ +8. Alcohol con-
sumption was divided into never, light, moderate, and
heavy drinking, with light drinking defined as consump-
tion of less than 5 g of ethanol per day; moderate drink-
ing as between 5 and less than 23 g per day; and heavy
drinking as 23 g or more per day. Smoking habit was
divided into never, former or current smoking of < 20,
and ≥ 20 pack-years. Regular exercise was classified into
no exercise, less than half an hour of exercise per day,
and half an hour or more of exercise per day. Hormone
use included all use for contraception, infertility, treat-
ment or hormone replacement therapy. Family history
was considered positive when a mother or sister had
breast cancer.
Definition of tumor subtypes and their assessment
We performed a medical record review for all case sub-
jects. ER, PR and HER2 expression was confirmed from
the original pathological reports. ER and PR status was
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frequency and intensity scores. Using the Allred score,
tumors scoring 0 or 2 were regarded as negative, and 3
or more as positive. HER2 expression was determined
by immunohistochemical (IHC) staining based on the
Hercep test. Tumors that showed 2+ were definitively
evaluated by fluorescence in situ hybridization (FISH).
Tumors were considered HER2-positive if they were ei-
ther scored 3+ by IHC staining, or 2+ by IHC and were
also HER2 amplified on the basis of FISH. With regard
to tumor subtypes, we adopted the IHC classification
described by Carey et al. (Carey et al. 2006), which cate-
gorizes breast cancer according to the expression status
of ER, PR and HER2 as follows: luminal (ER- and/or PR-
positive and HER2-negative), luminal/HER2 (ER- and/or
PR-positive and HER2-positive), HER2-rich (ER- and
PR-negative and HER2-positive), and triple-negative
(ER-, PR- and HER2-negative).Statistical analysis
The significance of differences in categorized demo-
graphic variables between cases and controls was eval-
uated using the Chi-square test. Subjects with unknown
data were excluded from the Chi-square test. Mean ages
were compared using the Mann–Whitney test. The
effect of each BMI indicator (current BMI, BMI at age
20 years, and BMI change) was estimated using odds
ratios (ORs) and 95% confidence intervals (CIs) by con-
ditional logistic regression models adjusted for potential
confounders, namely age, age at menarche (≤ 12, 13–14,
≥ 15), menopausal status (premenopause, postmeno-
pause), parity (0, 1–2, ≥ 3), age at first live birth (nul-
liparous, 17–23, 24–27, ≥ 28), family history of breast
cancer (yes, no), hormone use for contraception, infertil-
ity treatment or hormone replacement therapy (yes,
no), total exercise (none, < 0.5 h/day, ≥ 0.5 h/day),
and referral pattern to our hospital (patient discre-
tion, recommendation by family or friend, referral
from another clinic, secondary screening after primary
screening, or other). We excluded 6 subjects (2 cases
and 4 controls) with missing information on meno-
pausal status, leaving 2139 subjects for stratified ana-
lysis by menopausal status.
Interactions between respective BMI and menopausal
status were evaluated under the multiplicative model,
and the cross-product terms of these factors were
included in the multivariate conditional logistic regres-
sion models as interaction terms. The P value for inter-
action was calculated by a likelihood ratio test which
compared models with and without the interaction
terms.
All statistical analyses were carried out using STATA
ver. 11 (Stata Corp, College Station, TX). All tests weretwo-sided and P values < 0.05 were considered statisti-
cally significant.
Results
Table 1 shows the distribution of background character-
istics of the 715 breast cancer cases and 1430 controls.
Age and menopausal status were matched appropriately.
Compared to control subjects, cases were more likely to
have an early age at menarche (mean age ± SD: 13.3 ±
1.6 vs. 13.5 ± 1.7, P = 0.040), later first live birth among
parous women (mean age ± SD: 26.2 ± 3.4 vs. 25.9 ± 3.6,
P = 0.038), and a higher BMI (mean BMI ± SD: 22.5 ±
3.3 vs. 21.9 ± 3.2, P < 0.001). With regard to referral pat-
tern, cases were more likely to have a family recommen-
dation or referral from other clinics and less likely to
refer at patient discretion or as part of secondary screen-
ing after primary screening. Unexpectedly, case subjects
were more likely to do exercise for more than half an
hour per day than controls (P = 0.029). In contrast, the
other factors did not statistically significantly differ be-
tween the two groups.
Table 2 shows the association between current BMI,
BMI at age 20 years, or BMI change and breast cancer
risk. For all women, we observed strong positive associa-
tions between current BMI or BMI change and breast
cancer risk, with ORs in the overweight group (current
BMI ≥ 25) of 1.61 (95% CI : 1.23 - 2.11) compared to the
normal group (BMI range from 18.5 to 22) (Ptrend <
0.001). Similarly, OR for women with the highest BMI
change (BMI gain ≥ 8) was 2.56 (1.49 - 4.38) compared
to those of women with stable BMI change (BMI change
from −2 to +1.9) (Ptrend < 0.001). In contrast, no signifi-
cant association was seen between BMI at age 20 years
and breast cancer risk. On stratified analysis by meno-
pausal status, current BMI and BMI change were positively
associated with breast cancer risk only among postmeno-
pausal women (each Ptrend < 0.001). We also observed sta-
tistically significant interactions between current BMI, BMI
change, and menopausal status (Pinteraction = 0.0036 and
Pinteraction < 0.001, respectively).
Furthermore, we also evaluated the association be-
tween BMI and breast cancer risk by tumor subtype
(Table 3). As the effect of BMI by menopausal status
showed heterogeneity, we obtained stratified results by
menopausal status. Current BMI and BMI change were
positively associated with breast cancer risk for both lu-
minal and triple-negative subtypes among postmenopau-
sal women only, with ORs for each 1 kg/m2 increase in
current BMI of 1.14 (1.07 - 1.20) for the luminal subtype
(Ptrend < 0.001) and 1.21 (1.05 - 1.39, Ptrend = 0.008) for
the triple-negative subtype. Similarly, the effect of BMI
change was statistically significant for the luminal and
triple-negative subtypes among postmenopausal women
(Ptrend < 0.001 and Ptrend = 0.024, respectively). Further,










≤29 10 (1.4) 25 (1.8)
30-39 83 (11.6) 184 (12.9)
40-49 195 (27.3) 387 (27.1)
50-59 231 (32.3) 439 (30.7)
60-69 147 (20.6) 295 (20.6)
70-79 49 (6.9) 100 (7.0) 0.93
Mean age ± SD 52.4 ± 11.1 52.0 ± 11.3 0.410
Menopausal status
Premenopausal 340 (47.6) 680 (47.6)
Postmenopausal 373 (52.2) 746 (52.2) 1.00
Unknown 2 (0.3) 4 (0.3)
Age at menarche(year)
≤12 234 (32.7) 408 (28.5)
13-14 336 (47.0) 670 (46.9)
≥15 137 (19.2) 326 (22.8) 0.06
Unknown 8 (1.1) 26 (1.8)
Mean age ± SD 13.3 ± 1.6 13.5 ± 1.7 0.040
Parity
0 103 (14.4) 216 (15.1)
1-2 462 (64.6) 895 (62.6)
≥3 150 (21.0) 312 (21.8) 0.74
Unknown 0 (0) 7 (0.5)
Age at first live birth (year)
17-23 114 (15.9) 278 (19.4)
24-27 302 (42.2) 614 (42.9)
≥28 191 (26.7) 304 (21.3)
No birth 103 (14.4) 216 (15.1) 0.02
Unknown 5 (0.7) 18 (1.3)
Mean age ± SD 26.2 ± 3.4 25.9 ± 3.6 0.04
Age at menopause (year) (postmenopausal women only)
≤49 128 (34.4) 247 (33.1)
≥50 238 (63.8) 489 (65.6) 0.64
Unknown 7 (1.9) 10 (1.3)
Mean age ± SD 49.6 ± 5.0 49.4 ± 5.1 0.71
BMI (kg/m2)
<18.5 59 (8.3) 150 (10.5)
18.5-21.9 293 (41.0) 679 (47.5)
22–24.9 210 (29.4) 379 (26.5)
≥25 148 (20.7) 210 (14.7) < 0.001
Unknown 5 (0.7) 12 (0.8)
Table 1 Characteristics of breast cancer cases and cancer-
free controls (Continued)
Mean BMI ± SD 22.5 ± 3.3 21.9 ± 3.2 < 0.001
Alcohol consumption (g/day)
Never 444 (62.1) 900 (62.9)
Lighta 124 (17.3) 277 (19.4)
Moderateb 84 (11.8) 166 (11.6)
Heavyc 56 (7.8) 81 (5.7) 0.2
Unknown 7 (1.0) 6 (0.4)
Smoking (pack/year)
Never 594 (83.1) 1173 (82.0)
<20 79 (11.1) 162 (11.3)
≥20 34 (4.8) 84 (5.9) 0.560
Unknown 8 (1.1) 11 (0.8)
Total exercise (hour/day)
No 200 (28.0) 407 (28.5)
<0.5 279 (39.0) 629 (44.0)
≥0.5 228 (31.9) 384 (26.9) 0.03
Unknown 8 (1.1) 10 (0.7)
Family history of breast cancer
Yes 59 (8.3) 94 (6.6)
No 656 (91.8) 1336 (93.4) 0.16
Hormone use
Yes 98 (13.7) 197 (13.8)
No 604 (84.5) 1189 (83.2) 0.88
Unknown 13 (1.8) 44 (3.1)
Referral pattern to our hospital
Patient's discretion 205 (28.7) 496 (34.7)
Family recommendation 154 (21.5) 244 (17.1)
Referral from other clinics 206 (28.8) 251 (17.6)
Secondary screening after
primary screening
139 (19.4) 431 (30.1)
Others 6 (0.8) 4 (0.3) < 0.001
Unknown 5 (0.7) 4 (0.3)
Tumor subtype
Luminal (ER and/or PR+ and
HER2 -)
455 (63.6)
Luminal HER2 (ER and/or PR+ and
HER2+)
108 (15.1)
HER2 rich (ER and PR- and HER2+) 84 (11.8)
Triple negative (ER and PR- and
HER2-)
68 (9.5)
aLight drinker means consumption of < 5g ethanol/day. bModerate drinker means
consumption of between 5 and 23 g ethanol/day. cHeavy drinker means
consumption of >23 g ethanol/day.
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Table 2 Odds ratios (ORs) of breast cancer by the distribution of body mass index (BMI)
All (n=2145) Premenopausal (n=1020) Postmenopausal (n=1119)
Case / Control Case / Control Case / Control
(n=715 / 1430) ORs 95% CI (n=340 / 680) ORs 95% CI (n=373 / 746) ORs 95% CI Pinteraction
Current BMI (kg / m2)
< 18.5 59 / 150 0.93 0.66 - 1.33 41 / 83 1.11 0.70 - 1.76 17 / 67 0.66 0.36 - 1.23
18.5 - 21.9 293 / 679 1.00 (ref.) 175 / 377 1.00 (ref.) 118 / 299 1.00 (ref.)
22–24.9 210 / 379 1.26 0.99 - 1.59 84 / 144 1.08 0.75 - 1.55 125 / 234 1.38 0.99 - 1.93
≥ 25 148 / 210 1.61 0.99 - 1.59 36 / 74 0.88 0.55 - 1.41 112 / 136 1.98 1.39 - 2.82
Unknown 5 / 12 4 / 2 1 / 10
per1 kg / m2 increase 1.06 1.02 - 1.09 0.98 0.93 - 1.03 1.11 1.06 - 1.15
Ptrend < 0.001 0.373 < 0.001 0
BMI at age 20 years
< 18.5 120 / 295 0.79 0.61 - 1.01 72 / 174 0.81 0.57 - 1.14 47 / 119 0.74 0.50 - 1.09
18.5 - 21.9 452 / 842 1.00 (ref.) 221 / 412 1.00 (ref.) 230 / 429 1.00 (ref.)
22–24.9 116 / 229 0.91 0.70 - 1.19 39 / 75 0.88 0.55 - 1.39 77 / 153 0.95 0.67 - 1.33
≥ 25 17 / 35 0.81 0.43 - 1.51 5 / 12 0.77 0.25 - 2.39 12 / 23 0.88 0.40 - 1.92
Unknown 10 / 29 3 / 7 7 / 22
per1 kg / m2 increase 1.02 0.98 - 1.07 1.03 0.96 - 1.11 1.02 0.96 - 1.08
Ptrend 0.346 0.359 0.601 0.88
BMI change (from age 20 to the current age)
< −4 9 / 24 0.72 0.31 - 1.65 5 / 5 1.88 0.49 - 7.19 4 / 19 0.40 0.12 - 1.33
-4 to −2.1 30 / 83 0.80 0.51 - 1.26 16 / 27 1.22 0.62 - 2.42 14 / 56 0.58 0.30 - 1.14
-2 to +1.9 335 / 717 1.00 (ref.) 199 / 402 1.00 (ref.) 135 / 314 1.00 (ref.)
+2 to +4.9 221 / 421 1.05 0.84 - 1.32 86 / 185 0.86 0.61 - 1.22 134 / 233 1.15 0.83 - 1.58
+5 to +7.9 72 / 122 1.30 0.92 - 1.86 20 / 39 1.07 0.56 - 2.05 52 / 83 1.42 0.91 - 2.20
≥ +8 34 / 28 2.56 1.49 - 4.38 8 / 15 0.96 0.37 - 2.46 26 / 13 4.42 2.10 - 9.28
Unknown 14 / 35 6 / 7 8 / 28
per1 kg / m2 increase 1.06 1.03 - 1.10 0.95 0.90 - 1.01 1.12 1.07 - 1.17
Ptrend < 0.001 0.102 < 0.001 < 0.001
ORs were adjusted for age, age at menarche, menopause, parity, age at first live birth, family history of breast cancer, total exercise, hormone use, and referral pattern to our hospital.














Table 3 Associations between BMI and breast cancer risk by tumor subtype and menopausal status
Luminal (n=455) Luminal / HER2 (n=108) HER2 (n=84) Triple negative (n=68)
Premenopausal Postmenopausal Premenopausal Postmenopausal Premenopausal Postmenopausal Premenopausal Postmenopausal

















Current BMI (kg / m2)
< 18.5 30 1.23 0.70 -
2.15
9 0.65 0.28 -
1.50
5 0.63 0.16 -
2.56
2 0.66 0.09 -
4.83
3 0.48 0.04 -
5.64
4 0.34 0.06 -
1.82
3 - 2 0.43 0.04 -
4.12
18.5 - 21.9 123 1.00 (ref.) 61 1.00 (ref.) 31 1.00 (ref.) 23 1.00 (ref.) 10 1.00 (ref.) 22 1.00 (ref.) 11 1.00 (ref.) 12 1.00 (ref.)
22–24.9 51 0.92 0.59 -
1.45
76 1.46 0.94 -
2.29
17 1.95 0.64 -
5.99
13 0.81 0.27 -
2.42
12 3.67 0.69 -
19.5
18 0.80 0.26 -
2.47
4 - 18 2.74 0.81 -
9.22
≥ 25 28 0.96 0.55 -
1.68
71 2.13 1.33 -
3.42
3 0.17 0.03 -
1.03
14 2.38 0.75 -
7.58
4 2.66 0.13 -
52.8
11 1.04 0.33 -
3.30
1 - 16 7.51 1.84 -
9.22















- 1.21 1.05 -
1.39
Ptrend 0.363 <0.001 0.620 0.071 0.222 0.452 0.008
BMI at age 20 years
< 18.5 45 0.72 0.46 -
1.11
29 0.81 0.48 -
1.36
10 0.36 0.12 -
1.10
7 0.53 0.17 -
1.65
11 4.32 0.63 -
29.7
8 0.75 0.22 -
2.55
6 - 3 0.57 0.13 -
2.50
18.5 - 21.9 154 1.00 (ref.) 127 1.00 (ref.) 41 1.00 (ref.) 34 1.00 (ref.) 15 1.00 (ref.) 35 1.00 (ref.) 11 1.00 (ref.) 34 1.00 (ref.)
22 - 24.9 33 0.98 0.58 -
1.64




9 1.71 0.40 -
7.37
3 20.9 1.03 -
421.7
9 2.23 0.63 -
7.91
1 - 8 0.79 0.26 -
2.35
≥ 25 2 0.40 0.07 -
2.16
6 0.97 0.32 -
3.00
2 0.58 0.01 -
23.7
2 1.10 0.07 -
17.5
0 - 2 2.99 0.17 -
53.9
1 - 2 0.54 0.06 -
4.96
















Ptrend 0.235 0.617 0.876 0.314 0.852 0.264 0.838
BMI change (from age 20 to the current age)
< −4 3 1.27 0.25 -
6.38
4 0.81 0.21 -
3.16
1 0.47 0.01 -
19.5
0 - 0 - 0 - 1 - 0 -
-4 to −2.1 14 1.18 0.56 -
2.48
8 0.71 0.30 -
1.70
2 1.09 0.14 -
8.64
0 - 0 - 4 0.74 0.06 -
8.53
0 - 2 0.62 0.08 -
4.87
−2 to +1.9 141 1.00 (ref.) 64 1.00 (ref.) 32 1.00 (ref.) 26 1.00 (ref) 15 1.00 (ref.) 27 1.00 (ref.) 11 1.00 (ref.) 18 1.00 (ref.)
+2 to +4.9 58 0.79 0.52 -
1.20
84 1.41 0.91 -
2.18
17 1.02 0.37 -
2.81
18 0.89 0.33 -
2.39
6 0.60 0.07 -
5.25
13 0.34 0.11 -
0.99
5 - 19 2.33 0.70 -
7.76
+5 to +7.9 9 0.55 0.22 -
1.38
34 1.90 1.05 -
3.41
3 1.05 0.17 -
6.54
5 0.44 0.10 -
1.91
6 12.1 0.75 -
195.9
8 0.85 0.21 -
3.36















Table 3 Associations between BMI and breast cancer risk by tumor subtype and menopausal status (Continued)
≥ +8 6 0.98 0.33 -
2.96
18 5.50 2.14 -
14.1
0 - 3 5.66 0.31 -
102.3
2 - 2 2.40 0.17 -
33.3
0 - 3 4.41 0.31 -
61.9
Unknown 5 6 1 0 0 1 0 1
















Ptrend 0.054 <0.001 0.670 0.197 0.108 0.982 0.024
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BMI change after adjustment for BMI at age 20 years
(data was not shown). No significant associations be-
tween current BMI, BMI change and breast cancer risk
were seen for the other subtypes.
In premenopausal women, the suggestive inverse asso-
ciation of BMI change and breast cancer risk was
observed only for the luminal subtype, with an OR for
each 1 kg/m2 increase in BMI change of 0.93 (95% CI =
0.87 - 1.00, Ptrend = 0.054). We were unable to assess
ORs adequately among premenopausal women, particu-
larly for the triple-negative subtype, because of the pau-
city of subjects. To guess the associations among them,
we also showed an overall impact of BMI on risk
(Additional file 1: Table S1). The results were similar to
those when only postmenopausal women were included,
but the magnitude of association of current BMI and
BMI change with risk of the triple-negative subtype was
greater among postmenopausal women only than in all
women. This might suggest there were no trends of an
increased risk for the triple negative subtype among pre-
menopausal women.
We observed no association between BMI at age 20
years and risk for any tumor subtype.
Discussion
In this study, we evaluated the associations between
current BMI, BMI at age 20 years, BMI change and
breast cancer risk. We showed the possibility that het-
erogeneity may be present in the association between
adult weight gain and breast cancer risk by tumor sub-
type. Postmenopausal women with luminal and triple-
negative breast cancers showed the same impact of BMI
on breast cancer risk, despite the molecular and clinical
differences between these two subtypes. These findings
are consistent with those of several (Phipps et al. 2011;
Phipps et al. 2008) but not all previous studies (Yang
et al. 2007; Yang et al. 2011; Tamimi et al. 2011).
The biological mechanisms underlying these associa-
tions are unclear, but it is assumed that obesity influ-
ences breast cancer risk through multiple mechanisms.
One is a classic estrogen-dependent mechanism, in
which obesity contributes to lower serum levels of sex
hormone-binding globulin and higher circulating levels
of endogenous estrogen (Potischman et al. 1996). Almost
all reproductive factors that influence estrogen levels are
primarily associated with luminal-type tumors, but there
is also some evidence related to risk for non-luminal-
type tumors (Yang et al. 2007; Yang et al. 2011; Tamimi
et al. 2011; Islam et al. 2012). For example, our recent
study in Japanese suggested that age at menarche was
inversely associated with the risk of both luminal and
triple-negative breast cancer (Islam et al. 2012). Simi-
larly, the Polish Breast Cancer Study showed anassociation of earlier age at menarche with basal-like
tumors only (Yang et al. 2007). Other mechanisms might
relate to non-hormonal factors, such as an insulin-
related mechanism involving insulin, insulin resistance
and insulin-like growth factors (IGFs), or an inflamma-
tion-related mechanism (Stoll 2002; Kern et al. 2001).
IGFs, which stimulate mitogen-activated protein kinase
(MAPK) or Akt and increase cell survival, proliferation,
and migration through signaling cascades, are also con-
sidered to be risk factors for breast cancer (Hankinson
et al. 1998; Schernhammer et al. 2005). Davison et al.
(Davison et al. 2011) reported that IGFs promote cell
survival in triple-negative breast cancer cells. Further,
Maiti et al. (Maiti et al. 2010) suggested that metabolic
syndrome, characterized by high BMI and insulin resist-
ance, is significantly more prevalent in triple-negative
than non-triple-negative patients. On the basis of these
findings, we hypothesize that the combination of these
complex mechanisms contributes to an increased risk of
breast cancer, particularly of triple-negative subtypes. An
understanding of the etiology of less common subtypes
such as triple-negative tumors, which are the most clin-
ically aggressive, may be useful in the development of
prevention strategies.
Our observation of an inverse association between
BMI gain and the risk of premenopausal luminal breast
cancer is to our knowledge the first description in an
Asian population. A number of studies have evaluate the
effect of weight change on the risk of premenopausal
breast cancer, but most evidence to date is from studies
of ER and PR rather than HER2 disease, and the results
are inconsistent (Huang et al. 1997; Michels et al. 2012;
John et al. 2010; Weiderpass et al. 2004; Lahmann et al.
2005). In the Nurses’ Health Study, weight loss since age
18 years was inversely related to both ER+/PR+ and
ER-/PR- tumors (Michels et al. 2012). In contrast, a
case–control study in the San Francisco Bay Area
reported that inverse associations between obesity and
premenopausal breast cancer risk were limited to
ER+/PR+ tumors (John et al. 2010), which is consistent
with our present findings. The mechanisms underlying
this inverse association remain to be elucidated. Several
studies have suggested that women who are obese prior
to menopause are likely to have ovulatory insufficiency
or anovulatory cycles, resulting in decreased estrogen
and progesterone levels (Suzuki et al. 2011; Baer et al.
2010; Kawai et al. 2010; Key & Pike 1988), and we accept
this theory in interpreting our present result. However,
given our limited number of subgroup subjects and the
inconsistent results across studies, additional studies
with sufficient numbers of subjects of various ethnicities
are needed.
With regard to BMI at age 20 years, we found no statis-
tically significant association, but rather a slightly inverse
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excluded (Table 2). Several studies have suggested an in-
verse association between body weight in early adulthood
and the risk of breast cancer (Suzuki et al. 2011; Baer
et al. 2010; Kawai et al. 2010), but others have found no
significant association (Sanderson et al. 2002; Okasha
et al. 2003). A conclusive answer to this issue awaits fur-
ther study.
Our study had several methodological strengths. First,
it was conducted within the framework of the HER-
PACC study, which has a substantial number of subjects
and a high response rate to completion of the question-
naire (95%). Second, the potential confounding factors
of age and menopausal status were adjusted for by
matching. Finally, the single-institution design of the
study obviated the possibility of hormonal receptor or
HER2 status misclassification resulting from different
assay methods.
Since the present study was based on a hospital-based
case–control study, several methodological limitations
exist. First, the values for self-reported life-style factors
considered as potential confounding factors might have
been inaccurate. In particular, information about body
weight at age 20 years was collected retrospectively. Sec-
ond, the classification of tumor subtypes as defined in
our study is not identical to other published data due to
the lack of information on other tumor markers, such as
cytokeratin (CK) 5/6 expression, epidermal growth fac-
tor receptor (EGFR), and Ki67. We were therefore un-
able to precisely distinguish between basal-like and
triple-negative tumors, or between luminal A and lu-
minal B tumors. Finally, subject numbers in our sub-
group analyses were limited.
In conclusion, we found that current BMI and adult
weight gain are associated with the risk of luminal and
triple-negative breast cancer among postmenopausal
women only. Our results provide additional evidence for
these associations and suggest further etiological hetero-
geneity among tumor subtypes.
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